The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: Position statement of a United Kingdom consensus panel

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 959-969

  Mikhailidis, D P ^a   Wierzbicki, A S ^b   Daskalopoulou, S S ^c   Al Saady, N ^d   Griffiths, H ^e   Hamilton, G ^a   Monkman, D ^f   Patel, V ^g   Pittard, J ^h   Schachter, M ⁱ  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

^f East Barnet Health Centre   (United Kingdom)

^g GEORGE ELIOT HOSPITAL   (United Kingdom)

^h Chertsey Lane Surgery ^*  (United Kingdom)

ⁱ NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Combination therapy; Coronary heart disease; Ezetimibe; Guidelines; Low density lipoprotein cholesterol; Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; CERIVASTATIN; CREATINE KINASE; DAPSONE; DEXTROMETHORPHAN; DIGOXIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GLIPIZIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDAZOLAM; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; STATINE DERIVATIVE; STEROL DERIVATIVE; TOLBUTAMIDE; VITAMIN; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY DISEASE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MUSCLE DISEASE; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT OUTCOME; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CONSENSUS; GREAT BRITAIN; HUMANS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES;

EID: 21244456053     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X48447     Document Type: Review

References (57)

1. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
2. Grundy SM, Cleeman JI, Bairey Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
3. Williams B, Poulter NR, Brown MJ, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40
4. Department of Health. National Service Framework for Coronary Heart Disease. London: DoH, 2000
5. Joint British recommendations on prevention of coronary heart disease in clinical practice: British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998;80(Suppl 2):S1-29
6. Scottish Intercollegiate Guidelines Network. Secondary prevention of CHD following myocardial infarction. Edinburgh: SIGN, 2000
7. Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease. Edinburgh: SIGN, 1999
8. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-10
9. CMS Contract. Summary of Quality Indicators. Available from www.bma.org.uk/ap.nsf/content/QualityOutcomes [Last accessed 15 April 2005]
10. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-30
12. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
13. Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet 2003;361:1149-58
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
15. British Heart Foundation. Coronary Heart disease Statistics: Factsheet. 2004. Available from http://www.bhf.org.uk/professionals/index. asp?SecID=I5&secondlevel=519 [Last accessed 15 April 2005]
16. British Heart Foundation. BHF Health Professionals. Coronary Heart Disease Statistics 2004. Available from http://www.bhf. org.uk/professionals/ index.asp?SecID=15&secondlevel=519 [Last accessed 15 April 2005]
17. de Lusignan S, Dzregah B, Hague N, et al. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br J Cardiol 2003;10:223-8
18. Brady AJ, Oliver MA, Pittard JB. Secondary prevention in 24431 patients with coronary heart disease: Survey in primary care. BMJ 2001;322:1463
19. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
20. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511
21. Stein EA. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001;3(Suppl E):E11-6
22. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
23. Wooltorton E. Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ 2004;171:129
24. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68
25. Davis Jr HR, Zhu L, Hoos LM, et al. Niemann-Pick C1 Like 1 (NCP1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-92
26. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia. J Am Coll Cardiol 2002;40:2125-34
27. Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15
28. Melani L, Mills R, Hassman D, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with pravastatin in patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28
29. Kerzner B, Corbelli J, Sharp S, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24
30. Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein goals. Am J Cardiol 2004;93:1481-6
31. Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185-95
32. Gagne C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
33. Pearson T, Denke M, McBride P, et al. Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia. Program and abstracts from the American College of Cardiology 53rd Annual Scientific Session; March 7-10, 2004; New Orleans, Louisiana. Late Breaking Clinical Trials III
34. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:653-8
35. Medicines Control Agency. Adverse drug reactions online information tracking. Ezetimibe. Available from medicines.mhra.gov.uk [Last accessed 15 April 2005]
36. Ezetimibe (Ezetrol) Summary of Product Characteristics. Available from http://emc.medicines.org.Uk/emc/assets/c/html/displaydoc. asp?documentid=12091 [Last accessed 15 April 2005]
37. Kosoglou T, Statkevich P, Fruchart JC. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197-207
38. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905 [doi:10.1093/ eurheartj/ehi231]
39. Chiou P, Xydakis AM, Guyton JR, et al. Efficacy and tolerability of ezetimibe add-on therapy in bile acid sequestrant/niacin-based regimes. Arterioscler Thromb Vasc Biol 2004;24:132 [Abstract 467]
40. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile-acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795-7
41. Reyderman L, Kosoglou T, Statkevich P, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 2004;42:512-8
42. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
43. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
44. Ballantyne CM, Blazing MA, King TR, et al. Efficacy and Safety of Ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94
45. Nissen SE, Tuzcu M, Schoenhagen P, et al. for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med 2005;352:29-38
46. Ridker PM, Cannon CP, Morrow D, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med 2005;352:20-8
47. Lipka L, Sager P, Capece R, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Poster. European Atherosclerosis Society. Spain: Seville, April 2004
48. Goldberg AC, Sapre A, Liu J, et al. Ezetimibe Study Group. Efficacy and Safety of Ezetimibe Coadministered with Simvastatin in Patients with Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clin Proc 2004;79:620-9
49. Sager PT, Melani L, Lipka L, et al. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-18
50. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
51. Gagne C, Gaudet D, Bruckert E. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75
52. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-58
53. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-80
54. British Heart Foundation. Cholesterol screening in children and adolescents. Available from www.bhf.org.uk [Last accessed 15 April 2005]
55. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Medicinal Chem 2005;12:443-52
56. von Lintig FC, Lee D, Patel P, et al. Effectiveness of ezetimibe on hyperlipidaemia in HIV-1-infected patients. Antiviral Therapy 2004;9:L48 [Abstract 83]
57. Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005;21:333-8